Skip to main content

Table 1 Baseline characteristics of study participants

From: Vitamin-D2 treatment-associated decrease in 25(OH)D3 level is a reciprocal phenomenon: a randomized controlled trial

 

Study-1

Study-2a

Total

Vitamin-D2

Placebo

Vitamin-D3

Placebo

Number

24

25

23

25

97

Age, year

34.4 (5.1)

33.6 (6.3)

34.1 (6.8)

32.4 (6.4)

33.6 (6.2)

Female, number (%)

18 (75)

16 (64)

15 (65)

19 (76)

68 (70)

BMI, kg/m2

25.9 (4.5)

24.2 (3.2)

24.7 (3.0)

24.7 (4.4)

24.9 (3.9)

Sun exposure, hour/week

2.0 (1.3)

1.5 (1.3)

1.3 (0.9)

1.3 (1.1)

1.5 (1.2)

Milk intake, cup/day

0.6 (0.5)

0.5 (0.5)

0.3 (0.4)

0.3 (0.4)

0.4 (0.5)

Serum 25(OH)D2, nmol/L

UQ

UQ

39.6 (14.1)

37.5 (15.5)

19.3 (21.8)

Serum 25(OH)D3, nmol/L

52.3 (12.5)

52.4 (12.7)

45.4 (15.6)

45.2 (17.3)

48.8 (15.1)

  1. aReceived 50,000 IU of vitamin-D2 orally 4 days before obtaining baseline level. Data are means (SD), except as indicated. BMI, body mass index. 25(OH)D2, 25-hydroxyvitamin D2, 25(OH)D3, 25-hydroxyvitamin D3, 25(OH)D, total 25-hydroxyvitamin D. UQ, levels were undetectable in all participants of study-1 except for 2 participants in the vitamin-D2 arm where they were detectable but not quantifiable